This is the assessment of the relative effectiveness of ‘Sotagliflozin is indicated as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ≥ 27 kg/m2, who have failed to achieve adequate glycaemic control despite optimal insulin therapy.’
Below is the documentation provided by the Joint Assessment authoring team.
Final PTJA04 Assessment Report
Appendix – Literature search & in-excluded studies
External Comments – Factual Accuracy Check Manufacturer